EP Patent

EP2419727A1 — Interferon-alfa sensitivity biomarkers

Assigned to Merck Sharp and Dohme LLC · Expires 2012-02-22 · 14y expired

What this patent protects

The present invention provides biomarkers of sensitivity to interferon alfa (IFN-α). These IFN-α sensitivity biomarkers are useful, inter alia , to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-α, in methods of treating p…

USPTO Abstract

The present invention provides biomarkers of sensitivity to interferon alfa (IFN-α). These IFN-α sensitivity biomarkers are useful, inter alia , to identify patients who are most likely to benefit from treatment with pharmaceutical compositions of IFN-α, in methods of treating patients having a disease susceptible to treatment with interferon alfa, and in methods for selecting the most appropriate therapy for such patients.

Drugs covered by this patent

Patent Metadata

Patent number
EP2419727A1
Jurisdiction
EP
Classification
—
Expires
2012-02-22
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.